Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

Add AVEO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/26/2019 6:39:41 AM - Followers: 121 - Board type: Free - Posts Today: 1


Company website: 

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.


Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.


Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has approved on 8/28/17  FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)


Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints


AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.


AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  58%
20 Full Time Employees
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: Current Report Filing (8-k) 03/21/2019 04:33:06 PM
AVEO News: Confidential Treatment Order (ct Order) 03/18/2019 04:31:50 PM
AVEO News: Current Report Filing (8-k) 03/14/2019 04:06:44 PM
AVEO News: Annual Report (10-k) 03/14/2019 04:05:55 PM
AVEO News: AVEO Reports Full Year 2018 Financial Results and Provides Business Update 03/14/2019 04:05:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#4009   43% of AVEO shareholders are institutions who aren't Biotech Pharmer 03/26/19 06:39:41 AM
#4008   As mentioned, the FDA will not approve this harry crumb 03/25/19 03:49:40 PM
#4007   None of the top 7 biotech investors are harry crumb 03/25/19 03:47:53 PM
#4006   43% of AVEO is held by whales. Did Biotech Pharmer 03/25/19 02:06:15 PM
#4005   Nobody wants to buy this junk!, even at harry crumb 03/25/19 12:05:23 PM
#4004   Doesnt matter what they present to anyone! The harry crumb 03/25/19 11:54:03 AM
#4003   Hey harry, EUSA presenting P-3 data to CHMP Biotech Pharmer 03/25/19 09:48:04 AM
#4001   Yeah im in short! To .05! Fda’s decision harry crumb 03/12/19 02:00:53 PM
#3999   The wait may not be as long as biscotte 03/12/19 04:12:07 AM
#3998   Keep holding those shares. We'll be doing this omnedeusexmachina 03/12/19 02:33:23 AM
#3997   That is some great news brokenengineered 03/11/19 05:49:07 PM
#3996   Good....I’ll hold on to these shares that I BJ_Cooper 03/11/19 01:01:46 PM
#3995   https://apnews.com/business%20wire/b0dea4f93d5e41afbac225bb6daf6d84 Limey42 03/11/19 06:11:57 AM
#3994   We're buying the remaining float starting this morning, omnedeusexmachina 03/11/19 03:59:23 AM
#3993   Here we go Harry. You in? Biotech Pharmer 03/08/19 08:31:34 PM
#3991   I think all you longs have realized that harry crumb 03/07/19 03:11:33 PM
#3990   Poor souls who didnt get out, u had harry crumb 03/05/19 03:46:44 PM
#3989   Ah, first an formost to yur post, we harry crumb 03/05/19 08:02:15 AM
#3988   Gotta love those ambulance chasers. How come lbwagain 03/01/19 11:06:43 AM
#3987   * * $AVEO Video Chart 02-28-2019 * * ClayTrader 02/28/19 04:37:04 PM
#3986   Told everyone imo way back this was nothing harry crumb 02/28/19 01:22:55 PM
#3985   Here come the lawsuits! Next is the RS, harry crumb 02/28/19 01:18:12 PM
#3984   * * $AVEO Video Chart 02-26-2019 * * ClayTrader 02/26/19 04:31:48 PM
#3983   Turning bullish SilverNick 02/26/19 09:39:02 AM
#3982   * * $AVEO Video Chart 02-25-2019 * * ClayTrader 02/25/19 05:30:50 PM
#3981   * * $AVEO Video Chart 02-20-2019 * * ClayTrader 02/20/19 05:26:15 PM
#3980   * * $AVEO Video Chart 02-19-2019 * * ClayTrader 02/19/19 04:48:24 PM
#3978   Nice action & vol Wildbilly 02/19/19 10:18:56 AM
#3977   Shorts are gonna get killed here omg !!! Impacto 02/19/19 10:14:08 AM
#3976   Getting ready to rock and roll. BlueDragon 02/19/19 09:28:07 AM
#3974   Coming week is gonna be awesome. Very bullish !!! Impacto 02/17/19 03:21:05 PM
#3973   Good news from #GU19 Wildbilly 02/17/19 11:58:11 AM
#3972   AVEO Oncology Announces Oral Presentation of TIVO-3 Trial GM26 02/16/19 06:09:26 PM
#3971   Current report filed feb 15, 2019 Wildbilly 02/16/19 09:58:24 AM
#3970   https://ecancer.org/video/7686/latest-from-tivo-3--tivozanib-for-refractory-adva Biotech Pharmer 02/16/19 08:02:52 AM
#3969   Always seated with a bag of 20,000 shares biscotte 02/16/19 03:51:05 AM
#3968   Aveo will recover nicely ;) Impacto 02/15/19 08:58:27 PM
#3967   AVEO: joined BlackRock & tutes on the bottom, Wildbilly 02/15/19 03:31:14 PM
#3966   Breaking down that .61 wall, Wildbilly 02/15/19 02:59:09 PM
#3965   Adding. Huge buying opportunity!!! Impacto 02/15/19 02:46:00 PM
#3964   Sat Feb 16, 2019 ASCO presentation Phase 3 Wildbilly 02/15/19 02:25:58 PM
#3963   So Europe can use it, but you trust Shky 02/13/19 01:42:34 PM
#3960   Doesnt matter, dont u get it? Of course harry crumb 02/12/19 12:24:37 PM
#3958   LOL Harry. Show a time AVEO ever dipped Biotech Pharmer 02/11/19 11:22:43 AM
#3957   You must be unable to read the writing harry crumb 02/10/19 10:25:57 PM
#3956   Every time it touched this area, rebounded hugely. Impacto 02/09/19 04:07:49 PM
#3955   I am a Buyer, love it super oversold !!! Impacto 02/09/19 04:01:07 PM
#3954   Soon to be 8k will be released on harry crumb 02/09/19 01:52:16 AM
#3953   Well, well, well! I read the 8k and lbwagain 02/08/19 08:03:43 AM
#3951   Read the 8k people, aveo didnt disclose all harry crumb 02/07/19 04:55:00 PM